Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial.
Zhichao JiangYibin XieWen ZhangChunxia DuYuxin ZhongYuelu ZhuLiming JiangLizhou DouKang ShaoYongkun SunQi XueYantao TianShugeng GaoDongbing ZhaoAiping ZhouPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2024)
Perioperative DOS improved MPR significantly and tended to produce longer PFS compared to SOX in LAG/GEJ cancer in Asia, and might be considered as a preferred option for perioperative chemotherapy and worth further investigation.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- cardiac surgery
- clinical trial
- patients undergoing
- radiation therapy
- phase ii study
- double blind
- open label
- stem cells
- transcription factor
- phase ii
- phase iii
- papillary thyroid
- acute kidney injury
- squamous cell
- replacement therapy
- smoking cessation
- chemotherapy induced